Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (7981)	5/30/2000 11:25:00 AM
From: Vector1	Read Replies (1) \| Respond to of 9719

Tuck, I think ABSC is a good value in the low 30s. The VIPR ion channel technology is first rate and I expect a number of new deals for that system. My problem with the company is their business plan going forward. Are they a tools company or are they going to go after targets themselves. V1

To: tuck who wrote (7981)	5/30/2000 1:45:00 PM
From: scott_jiminez	Respond to of 9719

<< I gather PD patient populations are more homogeneous, thus resulting in fewer extraneous influences on DAT levels, and that the disease doesn't present such a complicated "neurotransmitter profile," as you put it. Would these be the reasons you like Altropane better for PD?>> The PD population is more homogeneous than the ADHD presentation in the sense that the dopaminergic deficit is quite well understood and is the accepted biochemical marker for the disease. While the NT pathology DOES go beyond dopamine (DA) in PD, the loss of DA neurons in the substantia nigra is so extreme as to fall outside any possible variation within an age matched control population. There is no equivalent marker, as far as I'm aware, for ADHD.